SurroMed

SurroMed was a biotechnology company specializing in biomarker discovery and the development of technologies for personalized medicine. Founded in 1998 and based in Menlo Park, California, the company developed the SurroScan platform, a high-throughput system for the simultaneous analysis of thousands of proteins and metabolites in biological samples. This technology enabled the identification of "biological surrogates" or biomarkers to monitor disease progression and drug efficacy. SurroMed's business model combined internal research with strategic collaborations with pharmaceutical and diagnostic companies. In 2005, the company's assets were acquired by the contract research organization PPD, Inc. for approximately $14.4 million.